This is starting to change with the government and private sector looking at other DfMA solutions such as panelised lightweight construction and CLT (cross-laminated timber), both of which have been successfully used in Singapore.
This approach is growing significantly in Asia.Private companies like Octopus in the UK are looking at expanding their remit and starting to invest in distribution of power..
The regulatory hurdles are not lessening.In fact, most believe they are tightening.The energy efficiency of data centres (PUE) is being increasingly regulated, especially in the EU.
In Germany, specific regulations about the use of recovered heat are coming into force.There is a great opportunity to use the recovered heat from DCs.
However, there are significant problems in exploiting this, and there are country and regional variations in how schemes can work..
In northern Europe, there is a precedent in community heating schemes, whereas in the UK this has never been common.They bring to life all data and stakeholder knowledge in one place, using a common language, so that everyone can understand every aspect.. Chips become the building blocks for our design.
They also become the building blocks for conversations between the people dealing with business strategy and those people dealing with design and implementation of the pharmaceutical engineering project.. We start off with the analysis of the business problem and then generate design elements.Chips will often appear as 3D models, but that's not what they are.
They are the embodiment of a system.The core purpose of the project drives the analysis that informs the selection of Chips..